GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it and certain of its shareholders intend to sell, subject to market and other conditions, 1.7 million American Depositary Shares (“ADSs”) representing ordinary shares of GW on the NASDAQ Global Market in an underwritten U.S. public offering. GW will grant the underwriters a 30-day option to purchase up to an additional 255,000 ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The price for the offering has not yet been determined. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), net profit margin is -24.50% and weekly performance is 18.98%. On last trading day company shares ended up $89.82. Analysts mean target price for the company is $90.00. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), distance from 50-day simple moving average (SMA50) is 37.14%.
TherapeuticsMD Inc (NYSEMKT:TXMD), announced that the Company will present at the 9th Annual JMP Securities Healthcare Conference taking place at the Westin New York Grand Central on June 24-25, 2014. TherapeuticsMD Inc (NYSEMKT:TXMD), fell 0.20% in last trading session and ended the day on $5.06. TXMD, Gross Margin is 76.20% and its return on assets is -66.40%. TherapeuticsMD Inc (NYSEMKT:TXMD), quarterly performance is -36.51%.
On June 09, 2014, Ventrus Biosciences Inc (NASDAQ:VTUS)’s shares dropped 2.90% to $1.34. The company on May 19 has entered into a merger agreement with Assembly Pharmaceuticals, a privately held biopharmaceutical company, in an all-stock transaction. Upon the completion of the merger, the combined company will be renamed Assembly Biosciences, Inc. and trade on the Nasdaq Capital Market under the ticker “ASMB.” Ventrus Biosciences Inc (NASDAQ:VTUS), shares moved up 3.65% in last trading session and was closed at $1.42, while trading in range of $1.28 – 1.45. Ventrus Biosciences Inc (NASDAQ:VTUS), year to date (YTD) performance is 25.15%.
Australian oncology drug development company Novogen Limited (ADR) (NASDAQ:NVGN), and CanTx Inc., its joint venture with Yale University, announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the potency seen in animal models to date, and the potential to prevent recurrence, Novogen and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer. Novogen Limited (ADR) (NASDAQ:NVGN). ended the last trading day at $3.99. Company weekly volatility is calculated as 6.80% and price to cash ratio as 10.28. Novogen Limited (ADR) (NASDAQ:NVGN), showed a negative weekly performance of 5.28
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), net profit margin is 24.70% and weekly performance is 8.46%. On last trading day company shares ended up $6.54. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI), distance from 50-day simple moving average (SMA50) is 13.63%.